Monday, 26 August 2019

FDA approves first generic version of Sabril to treat seizures

21 January 2019 | News

Complex partial seizures, a common type of seizures, start in a specific area of the brain and can affect consciousness.

The U.S. Food and Drug Administration approved the first generic version of Sabril (vigabatrin) 500 mg tablets for treating complex partial seizures, also called focal seizures, as an adjunctive therapy (given with another primary treatment) in patients 10 years and older who have responded inadequately to several alternative (refractory) treatments.

"Prioritizing the approval of generic drugs to compete with medicines that face little or no competition is a key part of our efforts to support access and reduce drug co